PRESS RELEASE On 1 and 2 July.

Gupta also stressed the importance of healthcare professional involvement in naloxone distribution, when a patient is co-prescribed naloxone with an opioid especially. While administration of opioid overdoses with naloxone is usually expected to reduce the proportion of witnessed opioid overdoses which bring about loss of life, Dr. Gupta emphasized that expanded naloxone access does not address the underlying causes of opioid overdose in fact it is just one small part of a positive path that may mitigate opioid overdoses. As part of ASA’s efforts to lessen the abuse and misuse of prescription medications, ASA collaborated with the White colored House Workplace of National Medication Control Plan to developa wallet-sized carddescribing the signs and symptoms of an overdose and instructions for assisting a person suspected of an overdose, including instructions to manage naloxone and call 911.Collier, M.D., Stephen E. Van Rompaey, Ph.D., Heidi M. Crane, M.D., M.P.H., Rosemary G. McKaig, Ph.D., Bryan Lau, Ph.D., Aimee M. Freeman, M.A., and Richard D. Moore, M.D. For the NA-ACCORD Investigators: Aftereffect of Early versus Deferred Antiretroviral Therapy for HIV on Survival The use of antiretroviral therapy has dramatically reduced disease progression and death among patients with human immunodeficiency virus infection,1,2 however the optimal time to begin with therapy is uncertain.3,4 Current guidelines suggest treatment for asymptomatic sufferers who have a CD4+ count of significantly less than 350 cells per cubic millimeter based on accumulating observational data.5,6 However, these recommendations note having less data from randomized clinical trials regarding the timing of the initiation of antiretroviral therapy.3,4 Data from randomized trials are limited by an evaluation of a subgroup of 477 patients7 from the Approaches for Administration of Antiretroviral Therapy trial ,8 which suggested that deferring antiretroviral therapy until the CD4+ count fell below 250 cells per cubic millimeter increased the risk of progression to the acquired immunodeficiency syndrome or death, in comparison with initiation of therapy at a CD4+ count of more than 350 cells per cubic millimeter.7,9 Several observational studies have examined the prognosis for patients who begin antiretroviral therapy at different CD4+ counts.5,6,10-16 However, these scholarly studies do not address the question of when to start antiretroviral therapy, since they don’t have a comparison band of individuals who deferred therapy.17,18 A few research have compared individuals with similar CD4+ counts who either deferred or initiated antiretroviral therapy, 19-24 but these studies didn’t have the statistical power and methods18,25,26 to examine differences in outcomes, among individuals with higher CD4+ counts particularly.